Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595926 | 1.00 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL29163531 | 1.00 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL29401750 | 1.00 | OPRD1 (0.49) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL894542 | 0.88 | OPRD1 (0.47) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL9543966 | 0.88 | OPRD1 (0.47) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL31359949 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL31158720 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL2081318 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL10207323 | 0.88 | OPRD1 (0.50) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL3929271 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| EP-3381913-B1 | 2-(((PYRROLIDIN-3-YL)CARBONYL)AMINO)-1H-IMIDAZOLE DERIVATIVES AS MELANOCORTIN RECEPTOR 1 (MCR1) AGONISTS FOR TREATING RHEUMATOID ARTHRITIS | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-03-31 | — | — | EP | disclosed |
| WO-2017090743-A1 | NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST | 田辺三菱製薬株式会社 | 2017-06-01 | — | — | WO | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | OPRD1 4277/4885NAMPT 1215/4885MEN1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.